PuraMed BioScience, Inc. Announces LipiGesic®M, Their Unique Migraine Treatment, is Now Available for Purchase at CVS, the 2nd Largest Drug Chain in the United States
SCHOFIELD, Wis., Jan. 25, 2012 /PRNewswire/ -- PuraMed BioScience, Inc. (OTCBB: PMBS) announced today that LipiGesic M, their clinically proven effective and safe, all natural product for the treatment of migraine headaches, is now available for purchase at CVS, the 2nd Largest Drug Chain in the United States. With the addition of over 7,000 CVS locations, LipiGesic®M is now available in approximately 15,000 stores nationwide.
"We are pleased to now have our LipiGesic®M product available in both the #1 and #2 Drug Chain stores in the United States. Between the nearly 8,000 Walgreens and 7,000 CVS locations nationwide, we believe our product is gaining the exposure needed to generate significant revenue," stated Russ Mitchell, CEO of PuraMed BioScience.
PuraMed BioScience, Inc. anticipates announcing additional distribution in chain drug stores in the near future.
About PuraMed BioScience, Inc.:
PuraMed BioScience, Inc. engages in the research, development and marketing of non-prescription medicinal and healthcare products. PuraMed has completed a double blind placebo clinical trial for its leading product, LipiGesic®M, a sublingual acute treatment for the relief from migraine headaches, which was published in the top-tier medical journal, Headache. Please see the following link to view the abstract of that study. http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4610.2011.01910.x/abstract. LipiGesic®M has national distribution and is available nationwide in some of the largest chain drug stores in the United States. In addition to LipiGesic®M, the Company also has plans to launch LipiGesic®H for tension-type headaches as well as LipiGesic®PM which provides a remedy for insomnia and other sleep disorders.
For more information on PuraMed, visit the Company website at www.PuraMedBioScience.com, and join the Company's group page on Facebook by searching "PuraMed BioScience."
This news release contains forward-looking statements regarding PuraMed BioScience and its future business plans, which statements involve known and unknown risks and uncertainties. Such risks and uncertainties may cause actual results and future achievements of PuraMed BioScience to be materially different than those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.
Investor Awareness, Inc.
Tony Schor or James Foy
SOURCE PuraMed BioScience, Inc.
More by this Source
PuraMed BioScience® Announces Interview on Big Biz Show Discussing LipiGesic® M
Jun 10, 2013, 08:00 ET
PuraMed BioScience Discusses Potential for Patent Portfolio Acquisition
May 30, 2013, 11:11 ET
PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756
May 23, 2013, 14:10 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.